Richard Cook
Corporate Officer/Principal bei University of British Columbia
Profil
Richard Cook is an Associate Professor at the University of British Columbia, where he has been working since 2013.
Prior to his current position, he worked as the Chief Medical Officer at Avagenesis Corp.
and Enlighta, Inc. Cook holds a doctorate degree from the University of Alberta and a graduate degree from the University of British Columbia.
Aktive Positionen von Richard Cook
| Unternehmen | Position | Beginn |
|---|---|---|
| University of British Columbia | Corporate Officer/Principal | 01.01.2013 |
Ehemalige bekannte Positionen von Richard Cook
| Unternehmen | Position | Ende |
|---|---|---|
| ENLIGHTA INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Avagenesis Corp.
 Avagenesis Corp. Miscellaneous Commercial ServicesCommercial Services Avagenesis Corp. engages in the development and commercialization of licensed, patent-pending and patented, automated bioprocessing, and cell-isolation technology for the isolation of regenerative cells from human adipose tissues for use in research and for cosmetic and aesthetic medicine. It uses a proprietary cellular bioprocessing technology. The company was founded on December 10, 2010 and is headquartered in Richmond, Canada. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Richard Cook
| University of Alberta | Doctorate Degree |
| University of British Columbia | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ENLIGHTA INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Avagenesis Corp.
Avagenesis Corp. Miscellaneous Commercial ServicesCommercial Services Avagenesis Corp. engages in the development and commercialization of licensed, patent-pending and patented, automated bioprocessing, and cell-isolation technology for the isolation of regenerative cells from human adipose tissues for use in research and for cosmetic and aesthetic medicine. It uses a proprietary cellular bioprocessing technology. The company was founded on December 10, 2010 and is headquartered in Richmond, Canada. | Commercial Services |
